ERLIN2 and nasopharyngeal carcinoma: These findings delineate a novel pathogenic mechanism in NPC, highlighting the KLF1/CLPTM1L/ERLIN2/SREBP1 regulatory cascade as a promising therapeutic target for NPC treatment.